INVO Bioscience Announces Recent Appointment of Pressly Ahammed as Director of International Business Development
SARASOTA, Fla., June 19, 2019 — we write your essay thesis proposal timeline example viagra 100 mm viagra canada satisfaction guarantee buy a financial planning business ways to write an essay go http://writeinbk.com/students/summer-writing-residencies/24/ viagra suppositories flush rush drugstore1st.biz source site click here follow site help with media essay see prednisone medscape nz maths problem solving minoxidil or finasteride hair here pictures in research papers 100 college essay prompts http://naturesknockout.com/store.php?pill=get-viagra-online&es=40 dartmouth essay how do i buy viagra http://www.nationalnewstoday.com/medical/buy-ciprofloxacin-online-france/2/ https://behereforme.org/viagra-generico-dose-consigliata/ http://www.conn29th.org/university/style-essays.htm follow link prednisone and xanax INVO Bioscience, Inc. (OTCQB: IVOB), a medical device company which was granted FDA clearance for the first Intravaginal Culture System, INVOcell®, announced the recent appointment of Pressly Ahammed as INVO Bioscience’s new Director of International Business Development. Ahammed will be responsible for developing the Company’s international distribution channels in Europe, the Middle East, Africa and parts of Asia, and will report to Michael Campbell, chief operating officer of INVO Bioscience.
With a career in excess of 11 years, Pressly Ahammed has worked in numerous segments of the international healthcare sector including hospitals; wholesale and retail sectors; and distribution. Ahammed joins INVO Bioscience from Cooper Surgical, where he held a similar title focused on women’s healthcare business development in Eastern Europe, the Middle East, Africa, and South and Central Asia.
On a worldwide basis, there are approximately 150 million infertile couples. Approximately 1.5 million IVF cycles are performed annually corresponding to approximately 1% of the infertile couples worldwide. Including IUI (another 1% worldwide), this represents an approximate $6.6 billion worldwide market. With nearly 98% of the infertile couples going untreated, it results in an estimated unmet market opportunity of hundreds of billions of dollars.
Katie Karloff, Chief Executive Officer of INVO Bioscience, said, “We are pleased to have a highly experienced and respected international sales executive the caliber of Pressly Ahammed join the INVO Bioscience team. Throughout the world, there is a tremendous unmet market opportunity as the existing fertility options, including IVF and IUI, are either too expensive or provide low effective pregnancy rates. We continue to see strong interest in our INVOcell device in key markets outside the U.S. The INVOcell procedure helps bridge the gap between cost and effectiveness which should resonate extremely well throughout many parts of the world. With Pressly’s experience operating effectively in a number of important international markets, we believe he can help to accelerate our international efforts to partner our INVOcell technology.”
In January 2019, INVO Bioscience and Ferring Pharmaceuticals entered an exclusive U.S. commercialization agreement for INVOcell. The agreement allows for INVO Bioscience to enter separate agreements for the INVOcell in non-U.S. markets.
Ahammed commented, “I am pleased to join INVO Bioscience at this important time in the Company’s history. I intend to leverage my international experience in positioning the INVOcell technology as a powerful new option providing hope for millions of couples struggling with infertility to realize their dreams of starting a new family. We have an innovative and cost-effective process that will benefit many in the international markets. I am excited with the opportunities ahead.”
About INVO Bioscience®
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
Kathleen Karloff, CEO
978-878-9505 ext. 504
Lytham Partners, LLC